Clinical Trial: A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
Study Status: Completed
Recruit Status: RECRUITING
Condition: Lymphoma
Study Type: INTERVENTIONAL
Official Title: A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
Brief Summary:
To find a recommended dose of valemetostat that can be given in combination with rituximab and lenalidomide to patients with follicular lymphoma.The safety and effects of this drug combination will also be studied
Read more